Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06500819 · ClinicalTrials.gov registry record · Phase 1
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
A Phase 1 study of Sarcoma and Neuroblastoma, sponsored by Crystal Mackall, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT06500819 is a Phase 1 study of Sarcoma and Neuroblastoma that is actively recruiting participants, run by Crystal Mackall, MD. The registered enrollment target is 41 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06500819, a Phase 1 study of Sarcoma and Neuroblastoma, is actively recruiting participants, sponsored by Crystal Mackall, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.
Conditions Studied
Interventions
- DRUG B7-H3CART Dose (Intravenous)
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06500819
The ClinicalTrials.gov registry entry for NCT06500819 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The listed sponsor is Crystal Mackall, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which B7-H3CART Dose (Intravenous) is the first listed.
NCT06500819 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06500819 about?
NCT06500819 is a clinical study titled "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors". The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.
What is the current status of trial NCT06500819?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2024-07-11. Estimated completion is 2029-07.
What conditions does trial NCT06500819 study?
This clinical trial studies the following conditions: Sarcoma, Neuroblastoma, Osteosarcoma.
What interventions are being tested in trial NCT06500819?
The interventions under investigation include: B7-H3CART Dose (Intravenous) (DRUG).
Who is sponsoring clinical trial NCT06500819?
This trial is sponsored by Crystal Mackall, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06500819 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A Study of CRD3874-SI in People With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.